期刊
ANNUAL REVIEW OF MEDICINE, VOL 63
卷 63, 期 -, 页码 171-183出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-med-050410-105655
关键词
BRAF; vemurafenib; GSK2118436; MEK; CTLA-4
Metastatic melanoma has historically been one of the most treatment-refractory types of cancer. Recent headway has been made in understanding the genetic underpinnings of this cancer. A subset of oncogenic events is amenable to targeting with drug therapy. BRAF-targeted therapies represent the first major breakthrough in systemic therapy for melanoma leveraging the new genetic knowledge. Ongoing translational research seeks to identify the most scientifically rational combination treatment strategies to build on single-agent targeted therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据